Clinical Trial: Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

U.S., April 17 -- ClinicalTrials.gov registry received information related to the study (NCT07533305) titled 'Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma' on March 03.

Brief Summary: The purpose of this study is to assess the efficacy and safety of QL1706 combined with nab-paclitaxel and cisplatin in first-line therapy for patients with advanced or metastatic esophageal squamous cell carcinoma. QL1706 is a anti-PD-1 and anti-CTLA4 antibody.

Study Start Date: May 01

Study Type: INTERVENTIONAL

Condition: QL1706 ESCC First-line Therapy

Intervention: DRUG: QL1706 plus nab-paclitaxel and cisplatin

QL1706 will be administrated at...